Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16465787 | 1.00 | DDB1 (0.54) | DDB1CRBNALDH1A1HRH1NISCH | |
| SCHEMBL16148496 | 0.93 | DDB1 (0.60) | DDB1CRBNHRH1 | |
| SCHEMBL15633085 | 0.86 | FPR2 (0.42) | DDB1CRBNLTA4HKCNH2 | |
| SCHEMBL15633084 | 0.86 | FPR2 (0.42) | DDB1CRBNLTA4HKCNH2 | |
| SCHEMBL15633110 | 0.81 | MAOB (0.47) | DDB1CRBNGSTP1MAOAMAOB | |
| SCHEMBL15633111 | 0.81 | MAOB (0.47) | DDB1CRBNGSTP1MAOAMAOB | |
| SCHEMBL20613502 | 0.80 | DDB1 (0.41) | DDB1CRBNHRH1 | |
| SCHEMBL19297511 | 0.80 | DDB1 (0.41) | DDB1CRBNMAOAMAOB | |
| SCHEMBL4789557 | 0.80 | SLC6A4 (0.44) | DDB1CRBN | |
| SCHEMBL15632987 | 0.80 | DDB1 (0.41) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906550-B1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2016-08-24 | — | — | EP | disclosed |
| EP-2906550-A1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2015-08-19 | — | — | EP | disclosed |
| US-8853412-B2 | Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| WO-2014056938-A1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2014-04-17 | — | — | WO | disclosed |
| US-20140099333-A1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140099333-A1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GPR65, GPR88 | DDB1 3271/4885CRBN 4044/4885ALDH1A1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.